Answers are grounded in this paper and cite their sources.
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor implicated in inflammation, immune modulation, and tumor progression. Head and neck squamous cell carcinoma (HNSCC) exhibits elevated AHR expression and basal AHR activity, suggesting that persistent receptor signaling may contribute to tumor behavior. While sustained activation by environmental AHR ligands has been linked to tumor-promoting phenotypes, the effects of chronic exposure to physiologically relevant endogenous AHR agonists remain poorly defined. Circulating tryptophan (Tryp) metabolites, including kynurenine and indole derivatives, are continuously present in human serum and collectively contribute to basal AHR activity. Here, we examined whether prolonged exposure to a defined mixture of serum-derived Tryp metabolites promotes aggressive tumor phenotypes in HNSCC. Using a custom dish-in-dish culture system to model sustained exposure, we observed persistent AHR activation in HNSCC cells, evidenced by induction of canonical target genes and nuclear AHR translocation. Transcriptomic profiling revealed upregulation of inflammatory and tumor-associated programs, including CSF3, MMP1, and AP-1-associated targets. Assay for Transposase-Accessible Chromatin (ATAC)-seq analysis demonstrated ligand-dependent chromatin remodeling and enrichment of inflammatory transcription factor motifs, supporting epigenetic reprogramming during prolonged AHR activation. Sustained Tryp metabolite exposure also enhanced cytokine secretion, proliferation, clonogenic survival, migration, and invasive capacity, many of which were attenuated by pharmacologic AHR antagonism. Together, these findings demonstrate that chronic exposure to endogenous Tryp metabolites drives sustained tumor-intrinsic AHR signaling and promotes aggressive phenotypes in HNSCC, identifying AHR as a potential contributor to tumor progression and a candidate therapeutic target in HNSCC tumors exhibiting elevated AHR activity.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: